Table III.
Follow-up data in CME (n = 31) and non-CME (n = 35) group
| Parameter | CME group (n = 31) n (%) |
Non-CME group (n = 35) n (%) |
P-value |
|---|---|---|---|
| Median follow-up [months] | 45 (36–48) | 78 (58–108) | |
| Local recurrence | 0/31 (0) | 5/35 (14.3) | 0.012 |
| Recurrence-free survival | 31/31 (100) | 30/35 (85) | 0.044 |
| Metastases: | |||
| Synchronous | 4 | 3 | |
| Metachronous | 3 | 3 | |
| Metastasis-free survival (patients with synchronous metastases excluded) | 24/27 (89) | 29/32 (91) | 0.278 |
| Overall survival (patients with synchronous metastases included) | 29/31 (94) | 24/35 (69) | 0.021 |